Synaffix BV

2:00 PM - 2:15 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 103
Synaffix BV is a biotech company that has established a proprietary, clinical-stage technology platform that enables best-in-class antibody-drug conjugates (ADCs) in terms of safety and efficacy.

Our technology out-licensing business has already translated into 5 clinical-stage ADCs, at least 18 distinct ADC programs being developed across our 13 partners and over $5.7Bn in total potential value from our out-licensing deals.

Our partners include top-tier biotech and pharma companies such as ADC Therapeutics, Mersana Therapeutics, Janssen, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics, Emergence Therapeutics, Hummingbird Bioscience, Amgen and CKD Pharm.

Synaffix offers a consolidated ADC platform technology that enables any company with an antibody to develop a proprietary, best-in-class ADC and our patent portfolio provides granted protection of any resulting Products through at least 2035.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Platform technology for best-in-class ADCs
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Placeholder Photo
VP, Business Development
Synaffix BV